SELPLG and acute myeloid leukemia: Interestingly, the spleen tumor burden was strongly and similarly reduced in both recipients of WT and Selplg–/– AML at 24 h post-chemotherapy, suggesting that spleen may not be a site where CD162-induced AML blast chemoresistance occurs (Figure 5D).